Video

Q&A With Dina Kao From University of Alberta: Working to 'Advance the Science' of Fecal Microbiota Transplant

Author(s):

Patients with C-Diff are being treated with fecal microbiota transplantation but there is still more research being done in the field to learn more about the potential benefits in the field.

Patients with C-Diff are being treated with fecal microbiota transplantation but there is still more research being done in the field to learn more about the potential benefits in the field.

Dina Kao, MD, from the University of Alberta was part of a team that presented the results of a study on the topic during Digestive Disease Week in Washintgon, DC. Kao said the procedure has become a common treatment option so work can now be done to see how it can be done for other conditions and helping as many patients as possible. "There's just so many unanswered questions when it comes to fecal transplant," she said.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Gideon Hirschfield, FRCP, PhD | Credit: UHN Foundation
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2024 MJH Life Sciences

All rights reserved.